ZIA CP010125 10445 (ZIA) | |||
---|---|---|---|
Title | New England Bladder Cancer Survival Feasibility Study | ||
Institution | NCI, Bethesda, MD | ||
Principal Investigator | Colt, Joanne | NCI Program Director | N/A |
Cancer Activity | N/A | Division | DCEG |
Funded Amount | $185,370 | Project Dates | 02/01/2008 - N/A |
Fiscal Year | 2010 | Project Type | Intramural |
Research Topics w/ Percent Relevance | Cancer Types w/ Percent Relevance | ||
Biochemical Epidemiology (45.0%) Cancer (100.0%) Cancer Survivorship (100.0%) |
Bladder (100.0%) | ||
Research Type | |||
Exogenous Factors in the Origin and Cause of Cancer Interactions of Genes and/or Genetic Polymorphisms with Exogenous and/or Endogenous Factors |
|||
Abstract | |||
Bladder cancer has diverse clinical outcomes, including a high rate of recurrence. Only tumor stage and grade have been consistently linked with bladder cancer recurrence and survival. There is a need to identify prognostic markers of future disease, including progression, in order to minimize the cost and discomfort of routine screenings for bladder cancer recurrence, and to identify patients who should be treated earlier and more aggressively. The recently-completed New England Bladder Cancer Case-control Study provides us with an excellent opportunity to study the clinical, host-genetic, and environmental determinants of prognosis and survival. Before launching a survival study, we are proposing here to conduct a study to determine the feasibility of following a population-based case series, and the ability to obtain complete information on patientsı vital status; treatment history; and tumor pathology, recurrence, and progression. We will select a sample of 50 patients; interview them (or, if deceased, their next-of-kin) to update their exposure information and to obtain information about where they have received health care, the types of treatment received, and whether their disease has recurred or progressed; and obtain medical records from their health care providers. We will then evaluate this information to determine participant and physician response rates and the completeness of the medical history information obtained. Based on our findings, we will decide whether to proceed with a full-scale survival study. |